Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
| Treament | Trials | |||||
|---|---|---|---|---|---|---|
| clinical deterioration | clinical improvement | deaths | PCR-negative conversion | |||
| RNA vaccine | - | - | 0.50 [0.11; 2.28], 2 RCTs, I2=0% inconclusive result | - | ||
| Non replicating viral vector | - | - | 0.20 [0.02; 1.72], 1 RCT, I2=0% inconclusive result | - | ||
| Inactivated virus vaccine | - | - | - | - | ||
| Ad26.COV2.S A EFFACER | 0 | - | - | - | - | |
| BBV152 | 0 | - | - | - | - | |
| BCG vaccination | 0 | - | - | - | - | |
| CureVac | 0 | - | - | - | - | |
| DNA vaccine | 0 | - | - | - | - | |
| protein subunit vaccine | 0 | - | - | - | - | |
| Sanofi/GSK recombinant protein vaccine | 0 | - | - | - | - | |
| SCB-2019 | 0 | - | - | - | - | |
| virus-like particles vaccine | 0 | - | - | - | - | |
| Zy-Cov-D (Zydus Cadila) | 0 | - | - | - | - | |
-
About us
-
Contact us
-
Method
Made with in Lyon
-
Credits
-
Privacy policy
-
